Pichichero M E, Casey J R, Block S L, Guttendorf R, Flanner H, Markowitz D, Clausen S
Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA.
Antimicrob Agents Chemother. 2008 Jul;52(7):2512-20. doi: 10.1128/AAC.00132-07. Epub 2008 Mar 10.
An a priori pharmacokinetic/pharmacodynamic (PK/PD) target of 40% daily time above the MIC (T >MIC; based on the MIC(90) of 0.06 microg/ml for Streptococcus pyogenes reported in the literature) was shown to be achievable in a phase 1 study of 23 children with a once-daily (QD) modified-release, multiparticulate formulation of amoxicillin (amoxicillin sprinkle). The daily T >MIC achieved with the QD amoxicillin sprinkle formulation was comparable to that achieved with a four-times-daily (QID) penicillin VK suspension. An investigator-blinded, randomized, parallel-group, multicenter study involving 579 children 6 months to 12 years old with acute streptococcal tonsillopharyngitis was then undertaken. Children were randomly assigned 1:1 to receive either the amoxicillin sprinkle (475 mg for ages 6 months to 4 years, 775 mg for ages 5 to 12 years) QD for 7 days or 10 mg/kg of body weight of penicillin VK QID for 10 days (up to the maximum dose of 250 mg QID). Unexpectedly, the rates of bacteriological eradication at the test of cure were 65.3% (132/202) for the amoxicillin sprinkle and 68.0% (132/194) for penicillin VK (95% confidence interval, -12.0% to 6.6%). Thus, neither antibiotic regimen met the minimum criterion of > or =85% eradication ordinarily required by the U.S. FDA for first-line treatment of tonsillopharyngitis due to S. pyogenes. The results of subgroup analyses across demographic characteristics and current infection characteristics and by age/weight categories were consistent with the primary-efficacy result. The clinical cure rates for amoxicillin sprinkle and penicillin VK were 86.1% (216/251) and 91.9% (204/222), respectively (95% confidence interval, -11.6% to -0.4%). The results of a post hoc PD analysis suggested that a requirement for 60% daily T >MIC(90) more accurately predicted the observed high failure rates for bacteriologic eradication with the amoxicillin sprinkle and penicillin VK suspension studied. Based on the association between longer treatment courses and maximal bacterial eradication rates reported in the literature, an alternative composite PK/PD target taking into consideration the duration of therapy, or total T >MIC, was considered and provides an alternative explanation for the observed failure rate of amoxicillin sprinkle.
在一项针对23名儿童的1期研究中,一种先验的药代动力学/药效学(PK/PD)目标——每日高于最低抑菌浓度(MIC)的时间达40%(T>MIC;基于文献报道的化脓性链球菌MIC(90)为0.06微克/毫升),通过每日一次(QD)的阿莫西林缓释多颗粒制剂(阿莫西林分散片)得以实现。每日一次的阿莫西林分散片制剂所达到的每日T>MIC与每日四次(QID)的青霉素V钾混悬液相当。随后开展了一项研究者设盲、随机、平行组、多中心研究,纳入579名6个月至12岁患有急性链球菌性扁桃体咽炎的儿童。儿童被随机1:1分配,接受为期7天的每日一次阿莫西林分散片(6个月至4岁475毫克,5至12岁775毫克)治疗,或接受为期10天的每日四次、10毫克/千克体重的青霉素V钾治疗(最大剂量为每日四次250毫克)。出乎意料的是,在治疗结束时的细菌清除率方面,阿莫西林分散片组为65.3%(132/202),青霉素V钾组为68.0%(132/194)(95%置信区间,-12.0%至6.6%)。因此,两种抗生素治疗方案均未达到美国食品药品监督管理局(FDA)通常要求的化脓性链球菌所致扁桃体咽炎一线治疗>或 =85%清除率的最低标准。跨人口统计学特征、当前感染特征以及按年龄/体重分类的亚组分析结果与主要疗效结果一致。阿莫西林分散片和青霉素V钾的临床治愈率分别为86.1%(216/日251)和91.9%(204/222)(95%置信区间,-11.6%至-0.4%)。一项事后PD分析结果表明,每日T>MIC(90)达所需60%能更准确地预测所研究的阿莫西林分散片和青霉素V钾混悬液在细菌清除方面观察到的高失败率。基于文献报道的较长疗程与最大细菌清除率之间的关联,考虑到治疗持续时间或总T>MIC的另一种复合PK/PD目标被提出,并为观察到的阿莫西林分散片失败率提供了另一种解释。